BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 11115082)

  • 1. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
    Woo KT; Lau YK; Wong KS; Chiang GS
    Kidney Int; 2000 Dec; 58(6):2485-91. PubMed ID: 11115082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
    Campbell R; Sangalli F; Perticucci E; Aros C; Viscarra C; Perna A; Remuzzi A; Bertocchi F; Fagiani L; Remuzzi G; Ruggenenti P
    Kidney Int; 2003 Mar; 63(3):1094-103. PubMed ID: 12631093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensin-converting enzyme gene polymorphism in IgA nephritis.
    Woo KT; Lau YK; Chan CM; Wong KS
    Ann Acad Med Singap; 2008 May; 37(5):372-6. PubMed ID: 18536822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis.
    Woo KT; Lau YK; Zhao Y; Liu FE; Tan HB; Tan EK; Stephanie FC; Chan CM; Wong KS
    Cell Mol Immunol; 2007 Jun; 4(3):227-32. PubMed ID: 17601378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteinuria and angiotensin converting enzyme (ACE) gene polymorphism.
    Woo KT; Lau YK
    Ann Acad Med Singap; 2000 May; 29(3):383-7. PubMed ID: 10976394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
    Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
    Shi X; Chen X; Liu S; Zhuang Y; Zhang Y
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):399-403. PubMed ID: 12137603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
    Tanaka H; Suzuki K; Nakahata T; Tsugawa K; Konno Y; Tsuruga K; Ito E; Waga S
    Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of high-dose losartan in IgA nephritis.
    Woo KT; Chan CM; Tan HK; Choong HL; Foo M; Vathsala A; Lee EJ; Tan CC; Lee GS; Tan SH; Lim CH; Chiang GS; Fook-Chong S; Wong SK
    Clin Nephrol; 2009 Jun; 71(6):617-24. PubMed ID: 19473629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy.
    Rocchetti MT; Centra M; Papale M; Bortone G; Palermo C; Centonze D; Ranieri E; Di Paolo S; Gesualdo L
    Proteomics; 2008 Jan; 8(1):206-16. PubMed ID: 18095357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteinuria: clinical signficance and basis for therapy.
    Woo KT; Lau YK
    Singapore Med J; 2001 Aug; 42(8):385-9. PubMed ID: 11764058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
    Yang Y; Ohta K; Shimizu M; Nakai A; Kasahara Y; Yachie A; Koizumi S
    Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; LarczyƄski W; Rutkowski B
    Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
    J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone.
    Hwang YC; Lee TW; Kim MJ; Yang MH; Ihm CG
    Korean J Intern Med; 2001 Jun; 16(2):105-9. PubMed ID: 11590896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
    Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
    Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATRA therapy restores normal renal function and renal reserve and prevents renal failure.
    Woo KT; Lau YK; Chan CM; Wong KS
    Ann Acad Med Singap; 2005 Jan; 34(1):52-9. PubMed ID: 15726220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria.
    Tse KC; Li FK; Tang S; Tang CS; Lai KN; Chan TM
    Lupus; 2005; 14(12):947-52. PubMed ID: 16425574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.